BOSTON SCIENTIFIC NEUROMODULATION CORPORATION
Manufacturer adverse-event records for BOSTON SCIENTIFIC NEUROMODULATION CORPORATI… come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2008–2026 · mid-book · typical Death-code · injury-heavy
Injury-mix signature
BOSTON SCIENTIFIC NEUROMODULATION CORPORATI… leans injury-heavy in event_type mix
Injury-coded event_type share is 91.4% (injury-heavy tercile) beside 0.70% Death-coded (typical). Volume band: mid.
What the Injury-mix reading shows for BOSTON SCIENTIFIC NEUROMODULATION CORPORATION
The standout signal for BOSTON SCIENTIFIC NEUROMODULATION CORPORATION is Injury-mix: 91.4% Injury-coded (injury-heavy) beside 0.70% Death-coded, on a mid-book footprint.
Mid-pack volume still shows a clear device fingerprint; the table below is the actionable layer for BOSTON SCIENTIFIC NEUROMODULATION CORPORATI…. Event_type Death/Injury codes differ from patient-outcome rows - see methodology.
Reports span 10 device types, led in this extract by Injury at 18,497 (91.4% of event_type total). Peak single-year volume reaches 9,509 reports across 18 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (10)
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.